Mutations in the epidermal growth factor receptor occur frequently in a number of human tumours including gliomas, non-small-cell lung carcinomas, ovarian carcinomas and prostate carcinomas. The type III epidermal growth factor receptor mutation (variously named EGFRvIIl, de2-7 EGFR or AEGFR), which lacks a portion of the extracellular ligand binding domain, is the most common. Here, we review the current status with regard to the role of EGFRvIIl in human cancers. A detailed discussion of the formation of EGFRvIIl and its structure at the protein level are likewise included along with a discussion of its more functional roles. The design and use (preclinical and clinical) of small molecule inhibitors, antibodies, and antisense oligonucleotides against wild-type EGFR are considered in detail as these strategies can be directly adapted to target EGFRvIIl. Finally, the status of EGFRvIIl targeted therapy is reviewed.
Introduction
An important aspect in regulation of cell growth and proliferation is the response of cells to growth factors. Growth factors are cell-secreted polypeptides that mediate their effect upon binding to cell surface growth factor receptors. Binding of a growth factor to its receptor initiates a series of intracellular signalling events, including receptor activation, stimulation of kinase cascades, and transcription factors finally leading to changes in gene transcription. Thus, the primary role of the growth factor receptors is to relay information provided by the extracellular milieu to the cell. The cellular outcome of this is restricted in time and is cell-type specific.
The epidermal growth factor (EGF) was found in the early fifties by Levi-Montalcini and Cohen, and was one of the first peptide growth factors to be discovered. In the mid-seventies a plasma membrane protein that binds EGF was reported and named epidermal growth factor receptor (EGFR). Subsequent analysis established that the EGFR was a 170-kDa membrane-spanning glycoprotein and belonged to the receptor tyrosine kinase family of growth factor receptors. EGFR is expressed in many different cell types originating from all three germ layers [1] .
Due to its role in mediating growth and proliferation the EGFR has been associated with a large number of human malignancies including: breast cancer, small cell lung cancer (SCLC), brain cancer, prostate cancer, and oral cancer [2] [3] [4] [5] [6] . The mechanisms of how EGFR become oncogenic are various including: autocrine growth factor loops, overexpression of and/or amplification of the EGFR gene, and deletions/mutations that render the receptor activity independent of ligand and thus constitutively active [2, 7, 8] .
Mutations in the EGFR gene are commonly found in many types of human tumours and deletions in the extracellular domain the most frequent. These deletions seem to have an activating effect on the receptor, giving cells expressing these truncated receptors a growth advantage [9, 10] .
The most common of these truncated receptors is the type III EGFR deletion mutant (EGFRvIIl, A801EGFR, de2-7 EGFR). Although EGFRvIIl is unable to bind EGF or other EGFR-binding ligands it is constitutively phosphorylated and able to activate downstream signalling cascades. However, the EGFRvIIl seems to utilize other signal transduction pathways as compared to the ligand activated EGFR. This difference in signalling between EGFRvIIl and EGFR may at least, partly, at the molecular level account for the increased malignancy of EGFRvIII-expressing cells [11, 12] . Because the EGFRvIIl is found only on tumour cells it is an ideal target for anticancer therapy. Several different strategies can be used to target the EGFRvIIl expressing cells, including EGFRvIIl specific antibodies, ribozymes, and kinase inhibitors.
The aim of this review is to give an update on the recent results regarding the EGFRvIIl and will focus on the genetic alterations that lead to the formation of the EGFRvIIl. Furthermore, the structure of the EGFRvIIl, the signal transduction induced by EGFRvIIl and finally the use of EGFRvIII as a therapeutic target for anticancer therapy, as well as the current status with respect to the pre-clinical use of EGFRvIII targeted therapy, will be addressed.
The EGFR gene and the formation of EGFRvIII
Haley et al. [1] published the complete exon-intron structure of the human EGFR gene in 1987. The human EGFR gene is located on chromosome arm 7pl 1-13 and consists of 26 exons spanning over 110 kilobases of DNA as shown in Figure 1 [13] . Exons 1 through 14 code for the extra cellular domain, while the transmembrane domain is contained within exon 15. The exons 16 through 26 code for the intracellular domain including the tyrosine kinase domain.
Analysis of sub domains at the protein level showed that their boundaries closely match those of the exons. Thus sub domain LI is encoded within exons 1-4, sub domain SI by exons 5-7, sub domain L2 by exons [8] [9] [10] [11] and sub domain S2 by exons 13-14 ( Figure 1 ) [14] .
The 5' half of exon 15 codes for the transmembrane domain (TM), while the second half encodes the highly charged, stop-transfer sequence or the juxtamembrane region. Exons 16-22 encode the intrinsic tyrosine kinase domain (TK.) of the EGFR. Downstream of the tyrosine kinase domain is a region involved in calcium influx and receptor internalisation called CAIN. The CAIN domain is composed of two regions and is contained within exons 23 and 24. The last exon, exon 26, contains a large untranslated region with two alternate polyadenylation sites [15] .
The type III epidermal growth factor receptor mutation was first observed as aberrant transcript in human glioblastomas. The aberrant transcript were shown to contain the entire exon 1 followed by a sequence starting at base 3 of exon 8.
The type III epidermal growth factor mutation can then be predicted from the apparent splice joining of exon 1 to exon 8. The splice was found to be in-frame, with the formation of a new codon (GGT) at the splice junction, which translates into a glycine residue (Figure 2 ) [16] .
The variant cDNA observed is likely to be generated, at least in most cases, as a consequence of a genomic deletion, since genomic deletions of the corresponding regions are detected in the tumours. The EGFRvIII gene/transcript is often found in tumours which also have normal amplified EGFR genes and presumably arises during the amplification process [17, 18] . However, because the EGFRvIII is a result of the joining of exon 1 to exon 8 of the EGFR gene, it may in some instances happen through alternative splicing (Figure 1 ). This finding is supported by the fact that EGFRvIII in some tumours is detected without EGFR gene amplification or rearangement [19] .
Structure of the EGFR and the EGFRvIII
The epidermal growth factor receptor (EGFR) is a 170 kDa transmembrane glycoprotein synthesized as a 160 kDa precursor and then N-glycosylated at 12 potential sites.
It is composed of a single polypeptide chain of 1186 amino acid residues and contains an extracellular domain, a single transmembrane domain and an intracellular part made up of a juxtamembrane region, a protein kinase domain and a carboxy-terminal region (Figure 3 ) [20, 21] . Six growth factors bind to the EGFR: epidermal growth factor (EGF), transforming growth factor-alpha (TGF-oc), amphiregulin, heparin-binding EGF-like growth factor, betacellulin, and epiregulin. Ligand binding to the extracellular domain of EGFR results in an altered three-dimensional conformation and dimerization of the receptor. Dimerization is not only important for activation of the intrinsic tyrosine kinase but also for the autophosphorylation of several C-terminal tyrosine residues [6, 21] . The tyrosine-autophosphorylated residues represent specific binding sites for cytoplasmic target proteins involved in signalling pathways.
Extracellular domain
The 621 amino acid residues of the extra cellular domain of EGFR can be subdivided into four domains: domain LI, SI, L2 and S2. Domain LI and L2 are right-handed beta-helices and form the ligand binding pocket. Domain SI and S2 are cysteine-rich domains. The many cysteine residues form approximately 22 disulfide bonds in the extra cellular domain of EGFR [6, 22] . EGFRvIII lacks amino acid residues 6-273 in the extra cellular domain as compared to EGFR resulting in a size of 145 kDa. The deletion removes a portion of the receptor just after the signal peptide and includes most of the cysteine-rich domain SI. However, because the deletion occurs after the signal peptide, the EGFRvIII can be properly targeted and inserted into the cell membrane. At the fusion junction the formation of a new glycine residue results in a unique primary sequence of EGFRvIII ( Figure 2 ) [23] . Recently, a model of the 3 dimensional structure of the EGFR has been made, based on the structure of the insulin-like growth factor-1 receptor [24] . The model suggests that a cleft in the EGFR is possibly the ligand-binding site and the second face of each of the LI and L2 domains contain candidate ligand binding sites. The lack of ligand binding to the EGFRvIII could thus be explained from this model as the EGFRvIII lacks the entire LI domain except for the amino acid residues 1-5, and two third of the SI domain, which eliminates a large portion of the binding pocket [24] . Despite this, the deletion may result in a structure, which mimics the conformational change induced by ligands in wild-type EGFR [19] .
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i-I Handling the deleted area. Modified from [17] . Also shown are the corresponding aminoacid sequences.
Transiiwiiihniiw domain
The single transmembrane domain is made up o\" 23 amino acid residues (622 644) [21] . Several alterations in the transmembrane domain seem to have no effect on receptor function. Amino acid substitutions analogous to those present in the transforming c-erb2 neu (member of EGFR family) oncoprotein, proline substitutions and shortening of the transmembrane domain does not result in constitutive activation or prevention ofligandinduced signal transduction by the EGFR [25] . Thus, whether or not this domain plays a role in receptor function still remains unknown.
The intracclliilar pan
The intraccilular part of the ECiFR consists of 542 amino acid residues. The juxtamembrane region, the region between the membrane and the t\ rosme kinase domain, has a regulatory function in receptor downregulation and sensitation. Three serme -threonme phosphorvlation sites are present in this region: Thr-654. Thr-66 1 ). and Ser-671 [21] . Amongst these phosphorylalion sites it is clear that protein kinase C (PKC) phosphorylates Thr-654 and that this PKX'-phosphorylation has an inhibiting effect on kinase activity and high allinity ligand binding to the ECiFR [20] .
The protein kinase domain (amino acids d l )0 l )54) contains the intrinsic tyrosine kinase of the receptor, which is capable of phosphorylating several cvtoplasmic target proteins as well as the receptor itself [6. 21] .
Autophosphorylation of specific lyrosine residues in the EGFR creates binding sites for several proteins containing a Src-homology 2 (SH2(-domain or a phosphotyrosine-binding ( PTB)-domain. Some of these phosphotyrosine-binding proteins are en/ymes (Src. phos- 
Dimcri/ation and EGFRvlII activation
A well-known feature of the intact EGFR is its ability to form dimers upon ligand binding. The dimerization alters the conformation of the two receptors and thereby activates their intrinsic tyrosine kinases leading to receptor autophosphorylation. The autophosphorylation triggers signal transduction. receptor internalisation and down-regulation. Several groups have studied EGFRvlII self-dimerizalion and although conflicting results exist, new results indicate that EGFRvlII does undergo self-dimerization comparable to the ligand-induced EGFR [27. 105] , Most interestingly the self-dimerization seems to rely heavily on a conformation induced by core glycosylation [105] . It is. also, possible that the EGFRvlII undergoes heterodimerization with other members of the c-erb family [27] . Tang et al. [47] showed that upon expression oC EGFRvlII in the MCF-7 human breast cancer cell line, the level of ErbB-2 phosphorylation increased, which could be due to heterodimerization with EGFRvlII.
As reported by different groups, the EGFRvlII is constitutively tyrosine phosphorylated despite the lack of ligand binding [19. 27. 28] . The level of tyrosine phosphorylation is. however, approximately 10" o of the level of ligand-activated EGFR and the major tyrosine autophosphorylation sites of EGFRvlII are Tyr-1068. Tyr-1148, and Tyr-1173. Mutations in any of these sites alone or in combination abolish the enhanced tumouritzenesis characteristic of the EGFRvlII. Likewise, muta-tions in the intrinsic tyrosine kinase domain also abolish the tumourigenesis of EGFRvIII [28] .
The EGFRvIII also fails to be downregulated upon autophosphorylation. Evidence from studies of EGFR suggests that autophosphorylation of EGFR results in a more open conformation that exposes the otherwise cryptic internalisation/lysosomal targeting motifs to the receptor trafficking machinery, thereby triggering receptor downregulation processes [29] . The low level of EGFRvIII tyrosine phosphorylation thus may not be sufficient for the EGFRvIII to reach the more open conformation that is required for triggering downregulation.
Signalling events activated by EGFRvIII
Attempts to understand the role of the EGFRvIII in tumourigenesis on the basis of the phosphorylated substrates has been problematic. Activation of the Ras/ Raf/MEK/ERK pathway (mitogen activated protein kinase signalling pathway) has long been thought to be a common event in oncogenesis.
Adapter molecules like She and Grb2 have both been found to associate with EGFRvIII and the former to be phosphorylated by the EGFRvIII. The main binding site of She is on Tyr-1148 and of Grb2 on Tyr-1068 [30] . Association of She with EGFRvIII has however only been demonstrated in the glioblastoma cell line, U87 MG, which also express EGFR and the interaction in this cell line is unclear [23] .
An increased GTP loading of Ras (GTP bound Ras is the active form) has also been demonstrated in EGFRvIII transfected U87 MG cells [30] , but could not be reproduced in cell lines expressing EGFRvIII but not EGFR [27] . Likewise, conflicting evidence for an EGFRvIII-mediated activation of the mitogen-activated protein kinase pathway exists. One group showed a small increase in ERK activation, though more weakly than ligand bound EGFR, but later found it to be selectively downregulated [19] . It has been suggested that this could be due to an increased expression of MAP kinase phosphatase-1 in EGFRvIII-expressing cells [11] .
Overall it seems likely that the mitogen-activated protein kinase signalling pathway does not play a major role in the enhanced malignancy of EGFRvIII-expressing cells.
With an inactive Ras/Raf/ERK pathway in mind, searches for other pathways activated by EGFRvIII were performed. The breakthrough came in 1998 when Moscatello et al. [12] found a high level of constitutively active phosphatidyl inositol 3-kinase (PI3-K) in EGFRvIII transfected fibroblasts, which were blocked by the EGFRvIII tyrosine kinase inhibitor AG1478. EGFRvIIIexpression and PI3-K activity also showed a correlation with anchorage-independent growth and transformed morphology of the NIH3T3 fibroblasts expressing EGFRvIII, as the cells when treated with the PI3-K inhibitor LY 294002 (Hypericin) returned to normal fibroblast morphology [12] . LY 294002 likewise inhibited anchorage-independent growth and proliferation in low serum medium [31] . In addition to PI3-K the group investigated the level of c-jun-N-terminal kinase (JNK) activity in these cells and found a basal high level of JNK activity, which was inhibited by AG1478 and LY 294002 and thus dependent on EGFRvIII kinase activity and on PI3-K activity [11] . Inhibition of the pathway led to an increase in apoptosis of EGFRvIII expressing fibroblasts [11] . PI3-K and JNK thus seem to act as a potential antiapoptotic signalling cascade in EGFRvIII transformed-fibroblasts.
Interestingly, a high level of JNK activity has also been found in cells transfected with either the constitutively active tyrosine kinase fusion protein Bcr-Abl or the constitutively active fusion protein Tpr-Met, which consists of the cytoplasmic tyrosine kinase domain of the HGF/SF receptor (Met) fused downstream of sequences encoded by the tpr gene [32, 33] . The high level of JNK activity was required for their transforming potential [32, 33] . This thus suggests that a high level of JNK activity might be characteristic of unregulated kinases with a high transforming potential, such as seen in fibroblasts expressing EGFRvIII, Trp-Met, or Bcr-Abl.
How, then, does this difference in signalling between ligand-activated EGFR and EGFRvIII arise. A recent study by Hashimoto et al. [34] demonstrates that She regulates EGF-induced activation of JNK, while Grb2 controls ERK activation. Thus, She might associate with EGFRvIII at a higher level than with ligand-activated EGFR and thus probably favours signalling to JNK.. This facts is supported by the observation that a mutation of the tyrosine residue Yl 173 of the EGFRvIII, the major She binding site, reduce phosphorylation to 35% that of EGFRvIII [28] . However, the relation between the upstream JNK activator PI3-K and She is unclear, but complexes consisting of She, PI3-K, Grb2-and the Grb2-associated protein 1 (Gabl) have been isolated indicating a role for She in PI3-K activation [34, 35] .
Another explanation for the different signalling properties of EGFRvIII and ligand-activated EGFR might be found in the constitutive nature of the EGFRvIII. It has been established that cells proliferate upon a transient activation of the Ras/Raf/ERK pathway by EGFR, and that a prolonged ERK activation results in growth arrest and differentiation [36, 37] . A constitutively active PI-3K/JNK pathway may thus be compatible with continuous growth, while an active Ras/Raf/ ERK pathway is not.
The transient nature of ERK activity in EGFRvIIItransfected cells indicates that it is regulated at a level downstream of the receptor and a role for the MAPK phosphatase 1 (MKP-1, CL100) in dephosphorylation of ERK has been suggested [11, 31] . MKP-1 activity is primarily regulated at the transcriptional level and its expression induced by JNK, thus supporting the hypothesis of a MKP-1 mediated inactivation of ERK [38] . The signalling network downstream of EGFRvIII as summarised in Figure 4 , thus seems to involve a novel constitutive active PI3-K/JNK pathway that induce MKP-1, which in turn dephosphorylates and thereby decrease the activity of ERK.
ECFRvIII and Bcl-X L
Bcl-X L is a member of the Bcl-2 protein family. The 15 Bcl-2 family members can be subdivided into two groups according to their function: the antiapoptotic members on one side and the pro-apoptotic members on the other side. Bcl-X L belongs to the antiapoptotic members which all exert anti-cell death activity and share sequence homology in some conserved motifs known as Bcl-2 homology (BH) domains [39, 40] . The molecular mechanism by which Bcl-X[_ exerts its antiapoptotic function is still not fully understood. One of its potential functions in preventing apoptosis could be through heterodimerization with one of the pro-apoptotic family members, e.g., Bax, and thereby inhibiting the apoptotic function of this pro-apoptotic member. How Bcl-X L might participate in a negative regulation of the complex molecular mechanisms that are central in apoptotic signal transduction, such as the release of mitochondrial apoptotic factors, cytochrome C and apoptosis-inducing factor (AIF), still has to be solved [39, 40] .
EGFRvlII seems to be involved in antiapoptotic signal transduction by upregulating the expression of Bcl-X L . It has been shown that glioma cells transfected with EGFRvlII have an increased rate of proliferation and a decreased rate of apoptosis both in vivo and in vitro, which contributes to an enhanced tumourigenicity compared to relevant control cells. The decreased rate of apoptosis in these EGFRvlII transfectants correlated with an increased expression of Bcl-X L , and this upregulation of Bcl-X L seemed to be dependent on tyrosine kinase activity of EGFRvlII [41] . Another study showed that glioma cells transfected with EGFRvlII have an increased resistance to the chemotherapeutic drug cisplatin in vitro. The increased resistance was associated with suppression of drug-induced apoptosis and an upregulation of Bcl-X L that seemed to be dependent on tyrosine kinase activity of EGFRvlII [42] . In both studies EGFR overexpression in glioma cells did not have the same increased effect on upregulation of Bcl-X L [42] . Recently, Moscatello et al. [43] have demonstrated that JNK. activation leads to Activating Protein 1 (AP-1) complex formation and upregulation of Bcl-X L (Figure 4) .
In summary the deletion of exon 2-7 removes inhibitory restraints that leaves the EGFRvlII in a state of partial activation, which is sufficient for a low level of autophosphorylation. The low level of autophosphorylation can trigger receptor signalling but is insufficient for exposure of endocytotic sequence codes necessary for down-regulation and attenuation of signalling [28] . Studies of the downstream signalling pathways have shown that an alternative pathway for cell survival exists. Through this PI3-K. activation of JNK results in AP-1 complex formation that upregulates Bcl-X L , which in turn promotes cell survival. It has been shown that EGFRvlII constitutively activates this pathway [12] .
The role of EGFRvlII in human cancer
So far the EGFRvlII has only been detected in human tumours; 16% of non-small-cell lung cancer (NSCLC) cells, 57% of high grade gliomas, 86% of low grade gliomas, 66% of paediatric gliomas, 86% of medullablastomas, 78% of breast carcinomas, and 73% of ovarian carcinomas [9, 18] . In prostate cancer expression of EGFRvlII seems to increase progressively with the gradual transformation from normal cells to malignant cells [44] . EGFRvlII has been examined in normal tissue of breast, lung, skin, ovary, colon, kidney, endometrium, placenta, brain and prostate glands [9, 18, 44] . In these tissues EGFRvlII has not been detected. The high prevalence in a wide variety of human tumours suggests that the presence of EGFRvlII is selected for during the process of tumourigenesis. Several studies support this hypothesis and strongly indicate a correlation between the expression of EGFRvlII and an enhanced tumourigenicity of tumour cells both in vitro and in vivo [45, 46] One of the first observations was that EGFRvlII expression seemed to be lost in cell lines established from gliomas expressing the variant receptor, suggesting either a growth disadvantage in vitro or a selection in vivo [7] . It was likewise found that glioma cells transfected with EGFRvlII had little or no increase in cell growth or proliferation in vitro [45] . However, when the glioma cells transfected with the EGFRvlII were implanted subcutaneously or intracerebrally into nude mice, the tumourigenic capacity was greatly enhanced [7] . Likewise when the EGFRvlII transfected cell line was mixed with the parental'cell line at 1:10,000 and 1: 50,000 ratios, the EGFRvlII transfected glioma cells had outgrown the parental cell line after 4-5 weeks by a ratio of 20 :1 [41] . Nagane et al. [41] also showed that the increased tumourigenicity of these cells in vivo was due to increased proliferation and reduced apoptosis.
Later it was found that EGFRvlII was able to induce changes characteristic of transformed cells in fibroblasts including: poor adherence, a spindle-shaped morphology, a disordered growth pattern, and lack of density enhanced growth inhibition [19] . In addition the EGFRvlll-transfected fibroblasts exhibited anchorage-independent growth as measured by growth in soft agar, and formed tumours when implanted subcutanuosly into athymic mice [19] .
The direct transformation of cells from a non-tumourogenic to a tumourogenic phenotype by EGFRvlII has been shown in an IL-3-dependent, non-tumourogenic murine haematopoietic cell line. Upon transfection with EGFRvlII this cell line was transformed into an IL-3-independent and ligand-independent malignant phenotype both in vitro and in vivo [47] . Figure 6 Schematic structure of the EGFRvIII substrate-ribozyme complex. Arrowhead indicates the cleavage site adjacent to the junction between exons I and VII present in EGFRvIII mRNA [95] .
The breast cancer cell line MCF-7 likewise exhibited enhanced tumourigenicity upon expression of EGFRvIII, including a 3-fold increase in colony formation in 1% serum and tumours formed six times faster in nude mice when compared to wt MCF-7 [47] . An increased invasiveness has also been observed for a small cell lung cancer cell line transfected with EGFRvIII as measured by the ability of cells to transverse a matrix gel, resembling the basal membrane [47a] .
A recent clinical study showed a correlation between EGFRvIII expression and poorer prognosis in patients with glioblastoma multiforme: mean survival time for patients with EGFRvIII-positive tumours was 4.5 ± 0.6 months, as compared to 11.2 ± 0.9 months for patients with EGFRvIII-negative tumours [48] .
These results indicate that high-level expression of EGFRvIII can transform cells in vitro and confers enhanced tumourigenicity to cancer cells both in vitro and in vivo. The enhanced tumourigenicity seems to be most pronounced in in vivo systems indicating possible interactions of EGFRvIII with other factors, not available in the in vitro system, which amplify its biological effect. Clinically EGFRvIII expression is correlated with poorer prognosis of glioblastoma multiforme.
EGFR as a therapeutic target
This review focuses mainly on the role of the type III EGFR mutation. However, before addressing the EGFRvIII as a potential therapeutic target, the different strategies for targeting EGFR will be discussed briefly. Many of the strategies used to target EGFR can be directly adapted to EGFRvIII. EGFR is known to be implicated in supporting the oncogenesis and progression of a number of solid tumours. These include head and neck squamous cell cancer, cervical cancer, renal cell cancer, lung cancer, prostate cancer, bladder cancer, colorectal cancer, pancreatic cancer, breast cancer, melanomas, gliomas, and menengiomas [49] . Although EGFR is not tumour specific it is frequently overexpressed on many epithelial-and ectodermal-derived tumours and thus represent a potential target for cancer therapy [50] .
Small molecule inhibitors of EGFR
The largest and most promising class of compounds targeting the EGFR are the small molecule inhibitors of EGFR. These molecules act by inhibiting the intrinsic tyrosine kinase of EGFR, either reversibly or irreversibly ( Figure 7 ) [51] . The most advanced EGFR tyrosine kinase (EGFR-TK) inhibitors belong to the anilinoquinazolines and act by competitively inhibiting ATP binding. The basic structure of an anilinoquinazoline contains a benzene ring fused to a pyrimidine ring and then via an aminogroup to another benzene ring ( Figure 5 ). Adding different side chains to the anilinoquinazoline, molecules with different potency to EGFR-TK were developed [51] . The clinically most advanced of these molecules are ZD-1839 (Iressa™) and CP-358,77 ( Figure 5 ). Another recently developed EGFR-TK inhibitor is EKB-569 with a puridin ring instead of the purimidine ring ( Figure 5 ) [52] [53] [54] .
ZD-1839 (Iressa™) developed by AstraZeneca is the EGFR-TK inhibitor which is furthest in development. ZD-1839 has numerous effects on tumour cells expressing EGFR including induction of cell cycle arrest, increasing apoptosis and reducing cell proliferation [55] . Numerous preclinical studies have shown that ZD-1839 is active and effective in in vivo animal models. Results have shown that ZD-1839 is active when given orally, highly selective for EGFR-TK and has significant antitumour effects against a number of human tumour xenografts which could be additive, or supra-additive when administered in combination with other cytotoxic compounds (paclitaxel, taxanes, topoisomerase II inhibitors and antimetabolites) [55] [56] [57] .
In clinical phase I -II studies ZD-1839 has been shown U> be well tolerated (Table I) . ZD-1839 had predictable pharmacokmelics (halt-life 45 hours) and the dose-limiting toxicity at 700 mg was diarrhoea [58 611 . In three of these studies an evaluation of response was reported [58 60] . Response was seen in ovarian, colorectal, prostate as well as head and neck cancer. and a high response was seen in patients with non-smallcell lung cancer (NSC'LC). The largest of these studies enrolled 127 patients of which X9 patients completed the first cycle. Amongst these. 29 patients had a partial response or stable disease for at least three months [58] . ZD-1839 is now being examined in phase III trials. Three randomised trials [14. 16 and 17] lead by Dr M. Ranson. Manchester. England, are ongoing but data from these trials are not yet available (AstraZeneca. Personal Communication). In trials 14 and 17 patients with NSCLC are treated with six cycles oi' gemcitabine/cisplatin or puclitaxel carboplatin. respectively. Patients are randomised to 0. 250 or 500 mg given concurrently and continued until disease progression. In trial 16. patients with advanced NSCLC. who have failed to react to treatment with 1 or 2 regimens, were randomised between 250 or 500 mg ZD-1839 daily until disease progression or intolerable toxicity.
Like ZD-1839. CP358.774 is a selective reversible EGFR-TK inhibitor developed by Plizer Inc. Pre-clinical studies have shown that CP358.774 is orally bioavailable, is well tolerated, blocks tumour cell division, produces cell cycle arrest and induces apoptosis [53, 62] . In addition these studies have established that CP358.774 has antitumour effect in animal models [53] . Preliminary results from phase II clinical trials show that CP358.774 in daily doses of 150 mg is well tolerated, with skin rash and diarrhoea forming the most adverse side effects [63 65 ]. CP358J74 showed antitumour activity in patients with squamous cell carcinomas of the head and neck. Of the 42 patients included, three patients had partial responses, seven patients had stable disease. while the rest remained on study (tumours were not tested for EGFR expression) [65] . Another study investigated the effect of CP358/774 following platinumbased chemotherapy in patients with advanced nonsmall-cell lung cancer (NSCLC) [64] . All patients had stage IIIB or IV or recurrent metastatic NSCLC and tumours were positive for EGFR. Of the 15 patients evaluated for tumour response, three patients obtained partial response and three patients with stable disease. Twenty five patients remain on-study therapy [64] . The 3-cyanoquinoline, EKB-569, is a new specific and irreversible inhibitor of EGFR-TK ( Figure 5 ). It binds covalently to EGFR and is a potent inhibitor of recombinant EGFR-TK, IC 50 = 1.33, and phosphorylation of EGFR in cells, IC 50 = 15 nm) [66] . EKB-569 has likewise proven able to inhibit the growth of xenotransplanted tumours that overexpress EGFR, given orally at doses of 10 mg/kg/day [66] . Furthermore a combination of EKB-569 and the non-steroid anti-inflammatory drug sulindac provided striking protection against colon tumour formation in APC Min/+ mice (>95% reduction in polyp numbers) [54] .
A number of other small molecule inhibitors of EGFR are currently being tested in pre-clinical trials which include: CI-1033, PD153O35, PD169414, PD168393/ PD160678, PD158780, and PKI116) [67] . Taken together these data indicate that targeting EGFR with small molecule inhibitors of EGFR-TK, either alone or in combination with other treatment modalities, may prove very effective in the treatment of EGFR-driven human carcinomas.
EGFR antibodies
Another approach to modulate the EGFR is by using monoclonal antibodies directed against the receptor (Figure 7 ). Important properties of these antibodies are competition with ligands (EGF and TGF-a), receptor downregulation and inhibition of EGFR tyrosine kinase activity.
The clinically most advanced of these antibodies is IMC-C225 (Cetuximab™), marketed by Imclone Systems Inc. IMC-C225 (formerly C225) was originally made by immunizing mice with EGFR of human epidermoid carcinoma cells raising several different murine monoclonal antibodies, including M225. To reduce immunogenicity of M225, a chimerized version (IMC- C225) was generated by attaching the murine Fv (variable) regions of the antibody with a human IgGl constant region [68] . Preclinical investigations have shown IMC-C225 able to inhibit proliferation, induce apoptosis, inhibit angiogenesis, inhibit invasion /metastasis, and inhibit repair/recovery after chemotherapy or radiation of EGFR positive tumour cells [69] [70] [71] [72] [73] . Clinical studies of the monoclonal chimeric antibody, IMC-C225, either alone or in combination with cytotoxic drugs has been completed ( Table 2) . Cohen et al. gave IMC-C225 as a single agent to 189 patients and found that the antibody was well tolerated. The most profound sides effects were asthenia, fever, nausea and acne [74] . In a study by Gunnett el al. 54 patients with renal cell carcinoma were given a loading dose of 400 mg/m 2 and a weekly maintenance dose of 250 mg/m 2 weekly. They found that the antibody was well tolerated and in 25% of the patients a response was observed, with disease stabilization for at least six months [75] . Baselga, Mendelsohn and Rubin have all combined IMC-C225 with cytotoxic agents. In a phase I study [76] , 52 patients were enrolled and 13 patients received a single dose of IMC-C225, 17 received weekly multiple doses and 22 patients were treated with weekly multiple doses and cisplatin at 5, 20, 50 or 100 mg/m 2 . The antibody was well tolerated and although it was a phase I study and therefore not designed for the observation of clinical response, more than 50% of the patients were found to have at least stable disease after 28 days. Mendelsohn et al. [77] enrolled 11 patients with head and neck cancer, and these were loaded with 100-500 mg/m 2 IMC-C225 and 100-250 mg/m 2 as the maintenance dose. Reversible adverse events were observed in the form of fever, allergic reactions and skin toxicities. Evidence of biological activity was found [77] . In the study by Rubin et al., the same loading and maintenance doses as above were used. The eight patients were heavily pretreated and had refractory or recurrent head and neck or colorectal cancer. In this small study, IMC-C225 in combination with cisplatin (six patients), irenotecan (one patient) or no chemotherapy (one patient), demonstrated that IMC-C225 had promising activity [78] . In a study by Ezekiel et al. IMC-C225 was administered as above to patients with head and neck cancer in combination with 70-76.8 Gy given twice daily. Although this was also a small study with 16 patients, response to radiotherapy was improved when compared to radiotherapy alone [79] .
Other antibody entities against EGFR are also being investigated for antitumour activity. Recently Yang X-D et al. [80] reported that a humanized monoclonal antibody, ABX-EGF, inhibited the growth of human tumour xenografts. Humanized monoclonal antibodies are less immunogenic than chimeric monoclonal antibodies, which again are less immunogenic than murine mono-clonal antibodies. Murine monoclonal antibodies frequently induce the human anti-mouse antibody (HAMA) response. However, any advantages of ABX-EGF over IMC-C225 remain to be established. Bispecific antibodies which have two different antigen binding regions (one for EGFR and one for an immunological effector cell) and therefore dual specificity have also been developed. Data have been published on three such antibodies. M26.1 F(ab')2 targets both the EGFR and CD3. This antibody reduced tumour cell growth when coated with human lymphocytes [81] . MDX-447 targets the EGFR as well as the IgG receptor CD64; data from phase I-II trials indicate immunological activity, good tolerability and some biological response in refractory patients [82, 83] . Like MDX-447, H22-EGF targets EGFR and CD64, treatment reducing tumour cell growth and enhancing immunologically mediated cellular toxicity [84] .
One major obstacle when using systemic administration of antibodies for antitumour therapy is the poor tumour penetration. This problem can be overcome by reducing the size of the antibody (enzymatic cleavage (Fab, F(ab')2) or genetic engineering (scFv, (scFV) 2 ) or by administering the antibody to compartments (spontaneous or surgically created) [85] .
Collectively, these data have shown that targeting the EGFR with specific antibodies is feasible with relative moderate toxicity and has a promising outlook for the future treatment of malignant tumours expressing EGFR.
Other trategies
A number of other strategies can be used for targeting EGFR. The most promising is the use of antisense oligonucleotides. Antisense oligonucleotides target the cells by hybridising to complimentary nucleic acid sequences, leading to decreased protein expression [86] . The antisense oligonucleotides can be directed against both EGFR ligands and the EGFR itself ( Figure 7 ). Experimental data show that EGFR ligand antisense oligonucleotides inhibit in vitro proliferation of ovarian cancer cells and have an additive effect when combined with paclitaxel or cisplatin in vitro [87] .
EGFRvIII as a prognostic and therapeutic target
A major obstacle for efficient antitumour therapy is lack of specificity. One way in which tumour specificity can be increased is the discovery of tumour-specific targets. The variant EGF receptor, EGFRvIII, is a very promising target for cancer specific therapy, as it is present with high frequency in several different tumour types and has not been detected in normal tissues as explained previously.
In principle, EGFRvIII-expressing cells can be targeted in three different ways: 1) as a direct target for toxic antibodies or modified viruses [88, 89] , 2) the function of the EGFRvIII can be targeted by ribozymes specific for EGFRvIII mRNA and specific inhibitors of the downstream signalling molecules such as PI-3K and JNK, or 3) EGFRvIII can be used to trigger an immunological response.
EGFRvIII antibodies
The first strategy tried was the use of monoclonal antibodies specific for the EGFRvIII. The antibodies were raised against a 14-mer synthetic peptide corresponding to the fusion junction of the EGFRvIII. The fusion junction represents a unique epitope characterised by an inserted glycine residue at position 6 between amino acid residues 5 and 274 (Figure 2) [89, 90] . Once generated, the antibody can be coupled to either a radioactive isotope or a cytotoxic drug. (For details see review by Wikstrand CJ et al. [23] ). The use of radioactive coupled antibodies also has the advantage of killing adjacent tumour cells that do not express the mutated receptor in a heterogeneous tumour. Y10 is an unarmed murine IgG2a monoclonal antibody specific for EGFRvIII and recognizes both the human and murine equivalents of EGFRvIII. Systemic treatment of mice bearing subcutaneous B16 melanomas (transfected to stably express EGFRvIII) with Y10 led to long term survival of all mice treated [91] .
Recently, the antibody method was further refined by the development of single-chain immunotoxins specific for EGFRvIII. The single chain immunotoxins are fusions of single-chain antibody variable domains against the fusion junction of EGFRvIII and protein toxins (e.g., Pseudomonas exotoxin A). These fusion proteins have the advantage of greater tumour penetration, due to their smaller size, as compared to intact antibodies [92] . Two such antibodies MR-1 (ETA) and scFv(14El)-ETA have been tested in animal systems. The MR-1 immunotoxin was effective in the treatment of EGFRvIII-positive neoplastic meningitis (derived from a glioma cell line (U87MG) transfected with EGFRvIII) in athymic rats. The median survival was estimated to be > 53 days, as compared to seven days for the saline controls. No adverse effects were seen with the doses used [92] .
Likewise, a systemic treatment of mice with ScFv (14E1)-ETA was able to completely suppress metastasis formation of Renca-lacZ/EGFRvIII tumours [93] . Clinical trials for the use of these antibodies in treatment of EGFRvIII-positive tumours are being designed.
These data indicate that EGFRvIlI-specific antibodies may form an effective therapy against human tumours expressing EGFRvIII.
Virus modifications
The viral vectors currently in use for gene therapy lack specificity with regard to the types of cells they infect.
For cancer gene therapy the EGFRvIII is a very promising target to confer cancer cell-specific infection. Retroviral vectors that specifically infect EGFRvIII-positive cells could thus potentially enhance both the safety and efficiency of gene delivery. Lorimer et al. [88] made an expression plasmid in which a single chain Fv antibody specific for EGFRvIII is inserted at a novel position within a disulphide-bonded surface loop near the native receptor binding site of the Moloney leukaemia virus ectopic envelope glycoprotein. The retroviruses containing the expression vector express the fusion protein and this binds both peptide antigen and EGFRvIII on cells. However, a major problem with these modified viruses is the lack of infection, which could be due to a failure to induce a conformational change within the envelope fusion protein to a fusogenic state or the target is simply too far from the cell membrane to permit membrane fusion. Thus, although this method seems promising it still has some major obstacles to overcome [88] .
EGFRvIII mRNA specific ribozymes
As a result of the deletion, the fusion junction of the EGFRvIII gene is created directly upstream of a GTA triplet, which is subsequently transcribed into a ribozyme target codon (GUA). The use of EGFRvIII mRNA-specific ribozymes might thus be a promising gene therapy approach for EGFRvIII-expressing tumours. Ribozymes are catalytically active subsets of small RNA molecules that possess the dual properties of RNA sequence-specific recognition, analogous to conventional antisense molecules, and site-specific cleavage of RNA substrates thereby intercepting gene expression and forestalling subsequent translation [94] .
Two groups have made such EGFRvIII mRNA specific-ribozymes. Yamazaki et al. [95] published the sequence of an EGFRvIII mRNA specific-hammerhead ribozyme in 1998. The hammerhead ribozyme ( Figure 6 ) mediated site-specific cleavage of the aberrant EGFR mRNA and were able to reduce growth of EGFRvIIIexpressing tumours. Halatsch et al. [94] used another type of ribozyme, the hairpin ribozyme, to construct an EGFRvIII mRNA specific-ribozyme. This ribozyme could reduce the EGFRvIII mRNA levels to 10% in U-87 glioblastoma cells overexpressing EGFRvIII, inhibit EGFRvIII-mediated proliferation by 69%, and decrease colony formation in soft agar by 95% [47] . Although the above results seem promising we are still a long way from implementing ribozymes into human cancer therapy, the major limitation still being in vivo delivery to the appropriate cells.
Small molecule inhibitors of EGFRvIII and downstream signalling molecules
The EGFRvIII tyrosine kinase and the downstream signalling network also contain potential targets for anticancer drugs. If, for example, the constitutively active receptor tyrosine kinase or either the PI3K or the JNK could be inhibited, the increased malignancy conferred to the cells by the EGFRvIII might be reversed. A small synthetic compound, tyrphostin AG1478, has some selectivity towards the EGFRvIII tyrosine kinase as compared to the EGFR tyrosine kinase. Using EGFRvIII-and EGFR-transfected glioma cell lines Han et al. [96] showed that AG1478 preferentially inhibited the growth, DNA synthesis, and receptor autophosphorylation of glioma cells expressing the truncated rather than the EGFR. The tyrphostin AG1478 thus represents the first inhibitor that preferentially inhibits proliferation of tumour cells expressing the EGFRvIII [96] .
The PI3K can be specifically inhibited by wortmannin, but has so far only been used in vitro. Moscatello et al. [12] found a blockage of anchorage-independent growth, growth in low serum media, and morphological reversion of EGFRvIII-transformed cells by wortmannin. It is, however, important to note that these inhibitors should be delivered specifically to EGFRvIII-expressing cells and not systemically.
Immunologica) response against EGFRvIII
Another attractive immunotherapeutic strategy against EGFRvIII-expressing tumours is to generate a host immune response to EGFRvIII [97] . Initial experiments showed production of EGFRvIII-specific antibodies in mice when immunized with a synthetic peptide (Pep-3) spanning the fusion junction of EGFRvIII [23, 98, 99] . Such a vaccination of C57BL/6J mice one week before being challenged with EGFRvIII-transfected tumour cells led to a significant improvement in the medial survival as compared to non-vaccinated animals. In addition, 5 mice (50%) in this group were alive with no evidence of tumour when the experiment was terminated at 80 days [97] .
Sampson et al. [100] likewise used a murine homologue of the EGFRvIII (m-EGFRvIII) stably transfected into the B16 melanoma cell line and the astrocytome cell line 560 to show that mice immunized with Pep-3-keyhole limpet hemocyanin (KLH) in Freud's adjuvant induced a humoral antitumour response against subsequent subcutaneous challenge with m-EGFRvIII-B16 and m-EGFRvIII-560 cells (potentially by antibody-dependent macrophage cytotoxicity (ADMC) or complement mediated cytotoxicity (CMC)) [100] . A phase I Pep-3 vaccination of human glioma patients is currently being initiated [85] . Another method by which to present EGFRvIII antigen is the use of antigenpresenting dendritic cells capable of initiating potent primary antitumour immune responses in vivo [85] .
Conclusion
In a large number of tumours, EGFR is mutated or overexpressed. As explained above EGFRvIII is a tumour-specific ligand independent, constitutively active variant of the EGFR. It is capable of transforming or increasing the malignancy of a number of cell lines and thus a potent oncoprotein. It is reasonable to assume that EGFRvIII plays an important role in the development and progression of several human cancers in vivo. It is thus critical that we understand in greater detail the molecular function of the EGFRvIII at the level of the receptor itself, its signal transduction capabilities, and which alterations in gene expression this leads to. Hopefully this will provide new targets for future anticancer therapy.
Taken together, the use of EGFR and EGFRvIII as targets for anticancer therapy is promising and because EGFRvIII is only found on cancer cells, the treatment can be selective for the cancer cells, while the normal tissues are spared and possible side effects seen with traditional treatments avoided. It is, however, crucial that molecular classification to ascertain which tumours express activated EGFR or EGFRvIII is carried out to identify patients who might benefit from biologically targeted therapies. This requires routine use of immunohistochemical techniques using commercially available antibodies to EGFR and EGFRvIII. In addition the EGFRvIII status might prove valuable as a prognostic marker.
